These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 26677455)
21. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562 [TBL] [Abstract][Full Text] [Related]
22. Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. Lenhard JR; Brown T; Rybak MJ; Meaney CJ; Norgard NB; Bulman ZP; Brazeau DA; Gill SR; Tsuji BT Antimicrob Agents Chemother; 2015 Dec; 60(3):1584-91. PubMed ID: 26711763 [TBL] [Abstract][Full Text] [Related]
23. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State. Belley A; Lalonde Seguin D; Arhin F; Moeck G Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327 [TBL] [Abstract][Full Text] [Related]
24. Safety profiles of old and new antimicrobials for the treatment of MRSA infections. Bassetti M; Righi E Expert Opin Drug Saf; 2016; 15(4):467-81. PubMed ID: 26764972 [TBL] [Abstract][Full Text] [Related]
25. Linezolid versus vancomycin for skin and soft tissue infections. Yue J; Dong BR; Yang M; Chen X; Wu T; Liu GJ Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD008056. PubMed ID: 26758498 [TBL] [Abstract][Full Text] [Related]
27. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies. Dunne MW; Talbot GH; Boucher HW; Wilcox M; Puttagunta S Drug Saf; 2016 Feb; 39(2):147-57. PubMed ID: 26715497 [TBL] [Abstract][Full Text] [Related]
28. Comparison of Outcomes among Adult Patients with Nosocomial Bacteremia Caused by Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus: A Retrospective Cohort Study. Wang JT; Hsu LY; Lauderdale TL; Fan WC; Wang FD PLoS One; 2015; 10(12):e0144710. PubMed ID: 26690351 [TBL] [Abstract][Full Text] [Related]
29. Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results. Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN Antimicrob Agents Chemother; 2016 Jun; 60(6):3817-20. PubMed ID: 27001823 [TBL] [Abstract][Full Text] [Related]
30. Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility. Jones RN; Moeck G; Arhin FF; Dudley MN; Rhomberg PR; Mendes RE Antimicrob Agents Chemother; 2016 May; 60(5):3174-7. PubMed ID: 26926647 [TBL] [Abstract][Full Text] [Related]
32. Should daptomycin-rifampin combinations for MSSA/MRSA isolates be avoided because of antagonism? Stein C; Makarewicz O; Forstner C; Weis S; Hagel S; Löffler B; Pletz MW Infection; 2016 Aug; 44(4):499-504. PubMed ID: 26797915 [TBL] [Abstract][Full Text] [Related]
33. Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia. Metersky ML; Frei CR; Mortensen EM Respirology; 2016 Jan; 21(1):157-63. PubMed ID: 26682638 [TBL] [Abstract][Full Text] [Related]
34. Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin. Dahesh S; Wong B; Nizet V; Sakoulas G; Tran TT; Aitken SL Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31235559 [TBL] [Abstract][Full Text] [Related]
35. Resistance in Vancomycin-Resistant Enterococci. Miller WR; Murray BE; Rice LB; Arias CA Infect Dis Clin North Am; 2020 Dec; 34(4):751-771. PubMed ID: 33131572 [TBL] [Abstract][Full Text] [Related]
36. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. Morrisette T; Miller MA; Montague BT; Barber GR; McQueen RB; Krsak M J Antimicrob Chemother; 2019 Aug; 74(8):2405-2416. PubMed ID: 31322694 [TBL] [Abstract][Full Text] [Related]
37. A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections. Chuang YC; Chen PY; Lin CY; Chen YC; Wang JT; Chang SC Sci Rep; 2018 Jan; 8(1):1632. PubMed ID: 29374204 [TBL] [Abstract][Full Text] [Related]
38. Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin. Delaportas DJ; Estrada SJ; Darmelio M Pharmacotherapy; 2017 Aug; 37(8):e90-e92. PubMed ID: 28543367 [TBL] [Abstract][Full Text] [Related]
39. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review. Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683 [TBL] [Abstract][Full Text] [Related]
40. New-Generation Antibiotics for Treatment of Gram-Positive Infections: A Review with Focus on Endocarditis and Osteomyelitis. Bloem A; Bax HI; Yusuf E; Verkaik NJ J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33920526 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]